Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 1/20 | 0.44 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.44 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.44 |
| ▸ | AXL | P30530 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 9/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KLK7 | P49862 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3575125 | 0.79 | MEN1 (0.46) | TRPV1MAPTHTT | |
| SCHEMBL3575166 | 0.76 | TRPV1 (0.42) | TRPV1JAK2TP53MAPTHTT | |
| SCHEMBL18247413 | 0.75 | POLB (0.41) | JAK2TP53MAPTHTTKLK7 | |
| SCHEMBL4021056 | 0.75 | EP300 (0.51) | EP300KAT2BKAT8AXLMAPT | |
| SCHEMBL23060423 | 0.71 | GAA (0.57) | TRPV1MAPT | |
| SCHEMBL26674527 | 0.71 | SIRT2 (0.43) | JAK2TP53MAPTHTTKLK7 | |
| Trifluoroacetic Acid SCHEMBL30325420 | 0.71 | KDM4C (0.40) | JAK2TP53MAPTHTTKLK7 | |
| SCHEMBL18247656 | 0.71 | MAPT (0.43) | MAPT | |
| SCHEMBL5894746 | 0.70 | AXL (0.72) | EP300KAT2BKAT8AXLMAPT | |
| SCHEMBL5660868 | 0.68 | AXL (0.50) | EP300KAT2BKAT8AXLMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7728005-B2 | Ether derivative | AJINOMOTO CO., INC. (JP) | 2010-06-01 | — | — | US | disclosed |
| US-20060270693-A1 | Ether derivative | AJINOMOTO CO., INC. (JP) | 2006-11-30 | — | — | US | disclosed |
| EP-1679296-A1 | ETHER DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2006-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270693-A1 | Ether derivative | UROD, IL5, IL17A | EP300 1839/4885KAT2B 2705/4885KAT8 1380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.